Cargando…

Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses

Dendritic cell-based cancer vaccines (DC vaccines) have been proved efficient and safe in immunotherapy of various cancers, including melanoma, ovarian and prostate cancer. However, the clinical responses were not always satisfied. Here we proposed a novel strategy to prepare DC vaccines. In the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yunkai, Guo, Xiaohan, Hu, Bo, He, Peng, Jiang, Xiaowu, Wang, Zuohuan, Zhu, Huaxing, Hu, Lina, Yu, Minghua, Feng, Meiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893120/ https://www.ncbi.nlm.nih.gov/pubmed/33643825 http://dx.doi.org/10.1016/j.apsb.2020.08.004

Ejemplares similares

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules
por: Bethune, Michael T., et al.
Publicado: (2018)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma
por: Giavina-Bianchi, Mara, et al.
Publicado: (2015)

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients
por: Camisaschi, Chiara, et al.
Publicado: (2018)

Prognostic impact of p53 and/or NY‐ESO‐1 autoantibody induction in patients with gastroenterological cancers
por: Hoshino, Isamu, et al.
Publicado: (2020)

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
por: Gong, Wenjie, et al.
Publicado: (2022)

Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
por: Alsalloum, Alaa, et al.
Publicado: (2023)

Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
por: Fujii, Shin‐ichiro, et al.
Publicado: (2022)

Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy
por: Hamaï, Ahmed, et al.
Publicado: (2011)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC
por: Klippel, Zandra K., et al.
Publicado: (2014)

NY-ESO-1 expression in solid tumors predicts prognosis: A systematic review and meta-analysis
por: Wang, Huiyu, et al.
Publicado: (2019)

Cancer stem-like cells with increased expression of NY-ESO-1 initiate breast cancer metastasis
por: Liu, Mai-Ying, et al.
Publicado: (2019)

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
por: Ramachandran, Indu, et al.
Publicado: (2019)

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
por: Bujas, T., et al.
Publicado: (2011)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma
por: Ebert, Lisa M., et al.
Publicado: (2012)

Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
por: Sabado, Rachel L, et al.
Publicado: (2013)

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015)

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
por: Lattanzi, Michael, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7eesksq1f4b2b8avh2943ktjf1